Enlie Pharmaceutical JSC

Enlie Pharmaceutical JSC FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Enlie Pharmaceutical JSC (BCP.VN) as of Oct 23, 2026 is 277.04 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -117.83 % — a change of -335.12% (higher).

FCF Conversion

277.04 %

YoY

-335.12%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Enlie Pharmaceutical JSC is 2024 277.04 % . FCF Conversion Rate (FCF/EBITDA) of Enlie Pharmaceutical JSC was 2023 -117.83 % . It decreases by -335.12% higher compared to the previous year.

The Enlie Pharmaceutical JSC FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
527.42 VND
Jan 1, 2018
68.27 VND
Jan 1, 2019
-263.56 VND
Jan 1, 2020
103.77 VND
Jan 1, 2021
558.40 VND
Jan 1, 2022
1,186.99 VND
Jan 1, 2023
-117.83 VND
Jan 1, 2024
277.04 VND
The Enlie Pharmaceutical JSC FCF Conversion history
YEARFCF ConversionYoY
277.04 %-335.12%
-117.83 %-109.93%
1,186.99 %+112.57%
558.40 %+438.13%
103.77 %-139.37%
-263.56 %-486.03%
68.27 %-87.06%
527.42 %-301.02%
-262.37 %-112.75%
2,057.47 %-3,106.91%
-68.42 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Enlie Pharmaceutical JSC Stock analysis

What does Enlie Pharmaceutical JSC do? Enlie Pharmaceutical JSC generates revenue primarily through the manufacture and commerce of pharmaceutical preparations, medical equipment, and health supplements. The company leverages its core expertise in these healthcare categories to serve the market, establishing its primary income streams around the production and sale of these essential health products. In addition to its pharmaceutical operations, the firm has diversified its business model by expanding into the real estate industry. This segment involves the development of various commercial and residential infrastructures which are then made available for lease, providing an additional layer of financial activity beyond its core healthcare focus. Enlie Pharmaceutical JSC is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Enlie Pharmaceutical JSC stock

FCF Conversion Rate (FCF/EBITDA) of Enlie Pharmaceutical JSC is 277.04 % in 2024.

FCF Conversion Rate (FCF/EBITDA) of Enlie Pharmaceutical JSC changed from -117.83 % to 277.04 %, representing a -335.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Enlie Pharmaceutical JSC since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Enlie Pharmaceutical JSC with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Enlie Pharmaceutical JSC

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Enlie Pharmaceutical JSC